Direct-acting antiviral agents and the path to interferon independence

Warren N. Schmidt, David R. Nelson, Jean Michel Pawlotsky, Kenneth E. Sherman, David L. Thomas, Raymond T. Chung

Research output: Contribution to journalReview articlepeer-review

Abstract

Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies. Studies of interferon-α-based therapies have helped define treatment parameters, and these treatment strategies have cured a substantial percentage of patients. However, interferon-α must be injected; there are problems with tolerability, adherence, and incomplete response in a large percentage of patients. New drug candidates designed to target the virus or the host have recently been introduced at an unprecedented pace. In phase I-III studies, these agents have exceeded expectations and achieved rates of response previously not thought possible. We are, therefore, entering a new era of therapy for HCV infection and interferon independence.

Original languageEnglish (US)
Pages (from-to)728-737
Number of pages10
JournalClinical Gastroenterology and Hepatology
Volume12
Issue number5
DOIs
StatePublished - May 2014

Keywords

  • DAA
  • NS3/4A Protease Inhibitor
  • Non-nucleoside
  • Nucleoside/Nucleotide

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Direct-acting antiviral agents and the path to interferon independence'. Together they form a unique fingerprint.

Cite this